SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    U Anyanwagu, I Idris, R Donnelly, Drug-Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism, Clinical Pharmacology & Therapeutics, 2016, 99, 4
  2. 2
    Jason R. Guertin, Elham Rahme, Colin R. Dormuth, Jacques LeLorier, Head to head comparison of the propensity score and the high-dimensional propensity score matching methods, BMC Medical Research Methodology, 2016, 16, 1

    CrossRef

  3. 3
    Jukka Hakkola, Jaana Rysä, Janne Hukkanen, Regulation of hepatic energy metabolism by the nuclear receptor PXR, Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2016,

    CrossRef

  4. 4
    Juan Pedro-Botet, Xavier Pintó, Una visión actualizada del tratamiento hipolipemiante de alta intensidad en los pacientes de alto riesgo cardiovascular, Clínica e Investigación en Arteriosclerosis, 2016, 28, 1, 19

    CrossRef

  5. 5
    Itori Saito, Kyoichi Azuma, Taro Kakikawa, Nobuyuki Oshima, Mary E Hanson, Andrew M Tershakovec, A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia, Lipids in Health and Disease, 2015, 14, 1

    CrossRef

  6. 6
    Anton P. van de Woestijne, Yolanda van der Graaf, Jan Westerink, Hendrik M. Nathoe, Frank L.J. Visseren, Effect of Statin Therapy on Incident Type 2 Diabetes Mellitus in Patients With Clinically Manifest Vascular Disease, The American Journal of Cardiology, 2015, 115, 4, 441

    CrossRef

  7. 7
    Henna Cederberg, Alena Stančáková, Nagendra Yaluri, Shalem Modi, Johanna Kuusisto, Markku Laakso, Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort, Diabetologia, 2015, 58, 5, 1109

    CrossRef

  8. 8
    Joan Rius Tarruella, Jesús Millán Núñez-Cortés, Juan Pedro-Botet, Xavier Pintó Sala, La diabetogenicidad de las estatinas: ¿son todas iguales? Estado de la cuestión, Clínica e Investigación en Arteriosclerosis, 2015, 27, 3, 148

    CrossRef

  9. 9
    Niki Katsiki, Manfredi Rizzo, Dimitri P. Mikhailidis, Christos S. Mantzoros, New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!, Metabolism, 2015, 64, 4, 471

    CrossRef

  10. 10
    Yongin Cho, EunYeong Choe, Yong-ho Lee, Ji Won Seo, Younjeong Choi, Yujung Yun, Hye Jin Wang, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang, Risk of diabetes in patients treated with HMG-CoA reductase inhibitors, Metabolism, 2015, 64, 4, 482

    CrossRef

  11. 11
    B. Cariou, Statines et risque de diabète : quelles évidences ?, Médecine des Maladies Métaboliques, 2015, 9, 3, 273

    CrossRef

  12. 12
    Roberta Florido, Annie Elander, Roger S. Blumenthal, Seth S. Martin, Statins and Incident Diabetes: Can Risk Outweigh Benefit?, Current Cardiovascular Risk Reports, 2015, 9, 4

    CrossRef

  13. 13
    Aris P Agouridis, Michael S Kostapanos, Moses S Elisaf, Statins and their increased risk of inducing diabetes, Expert Opinion on Drug Safety, 2015, 14, 12, 1835

    CrossRef

  14. 14
    Henna Cederberg, Markku Laakso, Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter], Diabetologia, 2015, 58, 8, 1962

    CrossRef

  15. 15
    H. Okuyama, Handbook of eggs in human function, 2015,

    CrossRef

  16. 16
    Peter P. Toth, An Update on the Benefits and Risks of Rosuvastatin Therapy, Postgraduate Medicine, 2014, 126, 2, 7

    CrossRef

  17. 17
    Michael S. Kostapanos, Christos V. Rizos, Moses S. Elisaf, Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases, Drug Safety, 2014, 37, 7, 481

    CrossRef

  18. 18
    Corrigendum, British Journal of Clinical Pharmacology, 2014, 78, 3
  19. 19
    Michel de Lorgeril, Patricia Salen, Do statins increase and Mediterranean diet decrease the risk of breast cancer?, BMC Medicine, 2014, 12, 1, 94

    CrossRef

  20. 20
    Barak Zafrir, Mohit Jain, Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications, Cardiovascular Drugs and Therapy, 2014, 28, 4, 361

    CrossRef

  21. 21
    Maciej Banach, Corina Serban, Wilbert S. Aronow, Jacek Rysz, Simona Dragan, Edgar V. Lerma, Mugurel Apetrii, Adrian Covic, Lipid, blood pressure and kidney update 2013, International Urology and Nephrology, 2014, 46, 5, 947

    CrossRef

  22. 22
    Michael J. Wilkinson, Luke J. Laffin, Michael H. Davidson, Overcoming toxicity and side-effects of lipid-lowering therapies, Best Practice & Research Clinical Endocrinology & Metabolism, 2014, 28, 3, 439

    CrossRef

  23. 23
    Massimiliano Ruscica, Chiara Macchi, Beatrice Morlotti, Cesare R. Sirtori, Paolo Magni, Statin therapy and related risk of new-onset type 2 diabetes mellitus, European Journal of Internal Medicine, 2014, 25, 5, 401

    CrossRef

  24. 24
    Casper N. Bang, Peter M. Okin, Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review, Current Cardiology Reports, 2014, 16, 3

    CrossRef

  25. 25
    Zoon H. Park, Alicia Juska, Detelin Dyakov, Ramesh V. Patel, Statin-Associated Incident Diabetes: A Literature Review, The Consultant Pharmacist, 2014, 29, 5, 317

    CrossRef

  26. 26
    Giovanni Corrao, Buthaina Ibrahim, Federica Nicotra, Davide Soranna, Luca Merlino, Alberico L. Catapano, Elena Tragni, Manuela Casula, Guido Grassi, Giuseppe Mancia, Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study, Diabetes Care, 2014, 37, 8, 2225

    CrossRef

  27. 27
    Eiman Jahangir, Sergio Fazio, Uchechukwu K. A. Sampson, Incident diabetes and statins: the blemish of an undisputed heavy weight champion?, British Journal of Clinical Pharmacology, 2013, 75, 4
  28. 28
    Eliano Pio Navarese, Antonino Buffon, Felicita Andreotti, Marek Kozinski, Nicky Welton, Tomasz Fabiszak, Salvatore Caputo, Grzegorz Grzesk, Aldona Kubica, Iwona Swiatkiewicz, Adam Sukiennik, Malte Kelm, Stefano De Servi, Jacek Kubica, Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus, The American Journal of Cardiology, 2013, 111, 8, 1123

    CrossRef

  29. 29
    Michael R. Jones, Oliseyenum M. Nwose, Role of Colesevelam in Combination Lipid-Lowering Therapy, American Journal of Cardiovascular Drugs, 2013, 13, 5, 315

    CrossRef

  30. 30
    Harumi Okuyama, Tomohito Hamazaki, Yoichi Ogushi, Rokuro Hama, Hajime Uchino, Hiroyuki Watanabe, Michio Hashimoto, Statins are Contraindicant to Diabetics - Urgent Proposal, Journal of Lipid Nutrition, 2013, 22, 2, 173

    CrossRef

  31. 31
    Kieren J. Mather, The vascular endothelium in diabetes—a therapeutic target?, Reviews in Endocrine and Metabolic Disorders, 2013, 14, 1, 87

    CrossRef

  32. 32
    Alexander Tenenbaum, Enrique Z Fisman, Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?, Cardiovascular Diabetology, 2012, 11, 1, 140

    CrossRef